Snaprx India Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 15-11-2024
- Paid Up Capital ₹ 3.41 M
as on 15-11-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -95.58%
(FY 2023)
- Profit 96.19%
(FY 2023)
- Ebitda 94.99%
(FY 2023)
- Net Worth -0.28%
(FY 2023)
- Total Assets 179.21%
(FY 2023)
About Snaprx India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.41 M, as per Ministry of Corporate Affairs (MCA) records.
Kamal Kukreja, Dinesh Kukreja, and Vijay Kukreja serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC283128
- Company No.
283128
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Snaprx India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Kukreja  | Director | 30-Jun-2016 | Current |
Kamal Kukreja  | Director | 30-Jun-2016 | Current |
| Dinesh Kukreja | Director | 30-Jun-2016 | Current |
Financial Performance and Corporate Structure Insights of Snaprx India.
Snaprx India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.58% decrease. The company also saw a substantial improvement in profitability, with a 96.19% increase in profit. The company's net worth dipped by a decrease of 0.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Snaprx India?
In 2023, Snaprx India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Purethanol Industries Private LimitedActive 6 years 8 monthsKamal Kukreja and Dinesh Kukreja are mutual person
- Innovate Organics Private LimitedActive 21 years 10 months
Kamal Kukreja and Dinesh Kukreja are mutual person
- Taap Choice Foods Private LimitedActive 19 years 10 months
Kamal Kukreja and Dinesh Kukreja are mutual person
- Sukhdata Distributors Private LimitedActive 19 years 10 months
Kamal Kukreja and Dinesh Kukreja are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Snaprx India?
Unlock and access historical data on people associated with Snaprx India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Snaprx India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Snaprx India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
